Adaptive Biotechnologies Corp (NASDAQ: ADPT) is -35.10% lower on its value in year-to-date trading and has touched a low of $2.28 and a high of $9.08 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ADPT stock was last observed hovering at around $3.11 in the last trading session, with the day’s gains setting it 0.07%.
Currently trading at $3.18, the stock is 16.77% and 2.50% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.15 million and changing 2.25% at the moment leaves the stock -30.50% off its SMA200. ADPT registered -51.82% loss for a year compared to 6-month loss of -33.75%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 8.53% gain in the last 1 month and extending the period to 3 months gives it a -10.92%, and is 13.98% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.49% over the week and 9.33% over the month.
Adaptive Biotechnologies Corp (ADPT) has around 709 employees, a market worth around $468.64M and $174.50M in sales. Profit margin for the company is -123.24%. Distance from 52-week low is 39.47% and -64.98% from its 52-week high. The company has generated returns on investments over the last 12 months (-43.59%).
The EPS is expected to grow by 16.34% this year
The shares outstanding are 145.08M, and float is at 140.68M with Short Float at 7.11%.
Adaptive Biotechnologies Corp (ADPT) Insider Activity
The most recent transaction is an insider sale by ROBINS CHAD M, the company’s CEO and Chairman. SEC filings show that ROBINS CHAD M sold 48,673 shares of the company’s common stock on Mar 05 ’24 at a price of $3.43 per share for a total of $0.17 million. Following the sale, the insider now owns 2.58 million shares.
Adaptive Biotechnologies Corp disclosed in a document filed with the SEC on Mar 05 ’24 that RUBINSTEIN JULIE (President) sold a total of 39,070 shares of the company’s common stock. The trade occurred on Mar 05 ’24 and was made at $3.47 per share for $0.14 million. Following the transaction, the insider now directly holds 0.47 million shares of the ADPT stock.
Still, SEC filings show that on Mar 05 ’24, BENZENO SHARON (Chief Commercial Ofc Imm Med) disposed off 29,390 shares at an average price of $3.44 for $0.1 million. The insider now directly holds 327,415 shares of Adaptive Biotechnologies Corp (ADPT).
